Chaudry Misbat, Banchs Jose, Chavez-MacGregor Mariana
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-3721, USA.
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Biomark Med. 2016;10(3):315-28. doi: 10.2217/bmm.15.124. Epub 2016 Feb 9.
Chemotherapy-induced cardiotoxicity, is a well-known and potentially serious complication strongly impacting the quality of life and overall survival of breast cancer patients. The current diagnostic approach to detect cardiac damage is the estimation of left ventricular ejection fraction by echocardiography. However, this approach exhibits less sensitivity toward early prediction of cardiomyopathy, not allowing for preventive strategies. Measurement of serum cardiac-specific biomarkers can be a valid diagnostic tool for identifying patients prone to developing cardiotoxocity and in whom closer cardiac monitoring and preventive strategies are pivotal. In this article, we review work done on biomarkers in recent years, with an emphasis on troponin and B-type natriuretic peptide, which are currently the most studied in this field. We also briefly discuss current and emerging imaging techniques for early detection of cardiomyopathy.
化疗引起的心脏毒性是一种众所周知且可能严重的并发症，对乳腺癌患者的生活质量和总生存期有强烈影响。目前检测心脏损伤的诊断方法是通过超声心动图评估左心室射血分数。然而，这种方法对心肌病的早期预测敏感性较低，无法采取预防策略。血清心脏特异性生物标志物的检测可以作为一种有效的诊断工具，用于识别易发生心脏毒性的患者，对于这些患者，密切的心脏监测和预防策略至关重要。在本文中，我们回顾了近年来关于生物标志物的研究工作，重点关注肌钙蛋白和B型利钠肽，它们是目前该领域研究最多的。我们还简要讨论了用于早期检测心肌病的现有和新兴成像技术。
